Phase I–II clinical trial with alpha-difluoromethylornithine—An inhibitor of polyamine biosynthesis

Alpha-difluoromethylornithine (DFMO) is an enzyme-activated, irreversible inhibitor of ornithine decarboxylase, the first enzyme in the synthesis of the polyamines putrescine, spermidine and spermine. DFMO has been shown to have a cytostatic and cytotoxic effect against various human tumor cell line...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer & clinical oncology 1987-08, Vol.23 (8), p.1103-1107
Hauptverfasser:	Horn, Yoav, Schechter, Paul J., Marton, Laurence J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast Neoplasms - drug therapy Chemotherapy Drug Evaluation Eflornithine - administration & dosage Eflornithine - adverse effects Eflornithine - therapeutic use Female Genital Neoplasms, Female - drug therapy Hearing Loss, High-Frequency - chemically induced Humans Leukocyte Count Male Medical sciences Middle Aged Pharmacology. Drug treatments Platelet Count Prostatic Neoplasms - drug therapy Stomach Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!